期刊文献+

5α还原酶抑制剂与前列腺癌预防 被引量:2

5-alpha reductase inhibitors and prostate cancer prevention
下载PDF
导出
摘要 5α还原酶抑制剂通过抑制5α还原酶降低双氢睾酮水平。应用5α还原酶抑制剂进行的前列腺癌预防研究显示,5α还原酶抑制剂可以降低前列腺癌发病率,但同时也出现高级别前列腺癌病例增加的现象,引起广泛关注。有研究和分析显示,5α还原酶抑制剂使前列腺体积缩小,同时也缩小Gleason评分为3分患者的前列腺癌体积,使得再次穿刺更容易发现Gleason评分为4分以上的前列腺癌。另外5α还原酶抑制剂显著提高前列腺穿刺诊断前列腺癌和高级别前列腺癌敏感度。笔者认为5α还原酶抑制剂不但不增加高级别前列腺癌的发生率,反而会帮助我们更早发现高级别前列腺癌。 5-alpha reductase inhibitors decrease the level of dihydrotestosterone (DHT) by inhibiting 5-alpha reductase. Trials on 5-alpha reductase inhibitors in prostate cancer prevention showed that they could significantly decrease the incidence of prostate cancer, but meanwhile increase high-grade cases as well. Recent studies demonstrated that 5-alpha reductase inhibitors could reduce not only the prostate volume but also the volume of Gleason grade 3 prostate cancer, which made easier the detection of higher-grade prostate cancer in the second biopsy. 5-alpha reductase inhibitors could also increase the sensitivity of prostate biopsy in detecting pros- tate cancer, particularly that of a higher grade. The evidence we have obtained leads to the conclusion that 5-alpha reductase inhibitors do not increase the incidence of high-grade prostate cancer, but on the contrary help its earlier detection.
作者 万奔
出处 《中华男科学杂志》 CAS CSCD 2012年第12期1059-1061,共3页 National Journal of Andrology
关键词 前列腺肿瘤 预防 5Α还原酶抑制剂 prostate cancer prevention 5-alpha reductase inhibitor
  • 相关文献

参考文献9

  • 1Andriole G, Bostwick D, Brawley O, et ol. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events ( REDUCE ) trial. J Urol, 2004, 172(4Pt 1) : 1314-1317. 被引量:1
  • 2Thompson IM, Coltman CA Jr, Crowley J. Chemoprevention of prostate cancer: The Prostate Cancer Prevention Trial. Prostate, 1997, 33(3) : 217,221. 被引量:1
  • 3Center MM, Jemal A, Lortet-Tieulent J, et al. International vari- ation in prostate cancer incidence and mortality rates. Eur Uroi, 2012, 61(6) : 1079-1092. 被引量:1
  • 4Dunn BK, Richmond ES, Minasian LM, et al. A nutrient ap- proach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trim (SELECT). Nutr Cancer, 2010, 62 (7) : 896-918. 被引量:1
  • 5Gaziano JM, Glynn R J, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men : The Physi- cians'Health Study Ⅱ randomized controlled trial. JAMA, 2009, 301 ( 1 ) : 52-62. 被引量:1
  • 6Choo R, Danjoux C, Morton G, et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in un- treated, Gleason score 4-7, clinically localized prostate cancer? Prostate, 2007, 67(15) : 1614-1620. 被引量:1
  • 7Marberger M, Freedland S J, Andriole GL, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: Lessons from the RE- DUCE study. BJU Int, 201,2, 109(8) : 1162-1169. 被引量:1
  • 8Reed AB, Parekh DJ. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer. Curr Opin Urol, 2009, 19(3) : 238-242. 被引量:1
  • 9Hussain M, Goldman B, Tangen C, et al. Prostate-specific anti- gen progression predicts overall survival in patients with metasta- tic prostate cancer: Data 'from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) ancI 9916. J Clin Oncol, 2009, 27(15) : 2450-2456. 被引量:1

同被引文献17

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部